ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.
Details are as follows:
| Oppenheimer’s 35th Annual Healthcare Life Sciences Conference |
| Conference Date: |
|
February 11-12, 2025 |
| Format: |
|
Company Presentation and one-on-one meetings |
| Presentation Time: |
|
Tuesday, February 11, 2025, 4:00 to 4:30 PM ET |
| Webcast Link: |
|
https://wsw.com/webcast/oppenheimer39/imab/2739496 |
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.
Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1 617-430-7579
pkelleher@lifesciadvisors.com
IR@imabbio.com
Source: I-Mab Biopharma
